BEACON-HCC:北美肝细胞癌治疗分配共识框架
通过改良德尔菲法,20名北美多学科专家制定BEACON-HCC肝细胞癌治疗分配框架,纳入肝内肿瘤负荷程度、血管侵犯及不良预后标志等特征。在29例真实病例初步验证中,外部专家推荐与BEACON-HCC推荐一致性为96.6%,与BCLC 2025推荐一致性为72.4%。
要点
- BEACON-HCC框架纳入肝内肿瘤负荷程度与血管侵犯程度等肿瘤生物学特征。
- 框架纳入EBRT、TARE及系统-局部联合治疗等新兴治疗方式。
- 初步验证显示专家决策与BEACON-HCC一致性高于BCLC 2025。
核心结论
- BEACON-HCC是基于共识的肝细胞癌治疗分配框架,纳入北美HCC患者可用的不断扩大的治疗选择范围。
- 专家治疗决策与BEACON-HCC系统显示出高度一致性。
- 计划通过HCC-Live Consortium使用临床经验数据进一步验证。
研究设计与样本
- 采用改良德尔菲流程,由20名北美肝病学、肿瘤内科学、外科学、放射学及放射肿瘤学多学科专家制定共识框架。
- 通过迭代讨论与投票形成共识,基于当前证据与专家意见。
- 初步研究使用29例真实世界患者病例,评估外部专家推荐与BEACON-HCC推荐及BCLC 2025推荐的一致性。
关键影像表现/征象
- BEACON-HCC框架纳入肝内肿瘤负荷程度与血管侵犯等精细临床特征。
- 框架纳入不良肿瘤预后标志物以匹配治疗分配与肿瘤生物学及治疗潜力。
- 框架纳入EBRT、TARE及系统-局部联合治疗等新兴治疗方式。
诊断标准与关键数值
- 在29例真实病例初步验证中,专家治疗决策与BEACON-HCC推荐一致性为96.6%。
- 在29例真实病例初步验证中,专家治疗决策与BCLC 2025推荐一致性为72.4%。
临床应用与阅片要点
- 影像报告中应描述肝内肿瘤负荷程度与血管侵犯程度,以支持BEACON-HCC框架下的治疗分配决策。
- 报告应关注不良肿瘤预后标志物,以辅助评估肿瘤生物学与治疗潜力。
- 影像评估可支持EBRT、TARE及系统-局部联合治疗等治疗方式的选择。
局限性
- 初步验证仅使用29例真实世界病例,样本量有限。
- 原文提到计划通过HCC-Live Consortium进行基于临床经验数据的进一步验证,表明当前验证尚不充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Optimal treatment decisions are challenging, and existing treatment allocation frameworks may not fully reflect the evolving therapeutic landscape or contemporary clinical practices in North America. Using a modified Delphi process, a multidisciplinary panel of 20 North American experts in hepatology, medical oncology, surgery, radiology, and radiation oncology developed a consensus-based treatment framework for HCC, termed the BEACON-HCC system. The framework was informed by current evidence and expert opinion through iterative discussion and voting. In a pilot study using 29 real-world patient cases, we assessed concordance between external expert recommendations and BEACON-HCC recommendations and Barcelona Clinic Liver Cancer (BCLC) 2025 treatment recommendations. The BEACON-HCC treatment allocation framework diverges from prior frameworks by incorporating nuanced clinical features such as the degree of intrahepatic tumor burden and vascular invasion, and adverse tumor prognostic markers, to align treatment allocation with tumor biology and therapeutic potential. Key innovations include the incorporation of emerging modalities such as external beam radiation therapy (EBRT), transarterial radioembolization (TARE), and systemic-locoregional combination therapies. In the pilot exercise, expert treatment decisions showed 96.6% concordance with BEACON-HCC recommendations and 72.4% concordance with BCLC recommendations. In conclusion, BEACON-HCC is a consensus-based framework for treatment allocation that incorporates the expanding range of therapeutic options available to patients in the North American HCC population. Expert treatment decisions showed a high concordance with the BEACON-HCC system; further validation using empiric clinical data is planned through the HCC-Live Consortium.
引用
- Singal, Agopian, Dawson, et al. BEACON-HCC: Best evidence and North American consensus on treatment allocation for hepatocellular carcinoma. Hepatology. 2026. PMID: 42565685. doi:10.1097/HEP.0000000000001834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。